NYSE:GMED Globus Medical (GMED) Stock Price, News & Analysis $75.62 +1.22 (+1.63%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$75.94 +0.31 (+0.41%) As of 10/2/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Globus Medical Stock (NYSE:GMED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Globus Medical alerts:Sign Up Key Stats Today's Range$74.22▼$76.1650-Day Range$73.61▼$88.4852-Week Range$56.50▼$101.40Volume1.31 million shsAverage Volume1.55 million shsMarket Capitalization$10.15 billionP/E Ratio19.34Dividend YieldN/APrice Target$99.46Consensus RatingModerate Buy Company Overview Globus Medical, Inc. is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies. The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery. Globus Medical also offers products for orthopedic trauma, including fixation systems and other devices used to treat fractures and support bone healing. Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical serves customers in the United States and international markets through direct sales and distribution channels. In 2023, the company completed its combination with NuVasive, expanding its product offerings and global presence in spine and related musculoskeletal care. Dan Scavilla serves as the company’s chief executive officer, while founder David C. Paul serves as executive chairman.AI Generated. May Contain Errors. Read More Globus Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreGMED MarketRank™: Globus Medical scored higher than 82% of companies evaluated by MarketBeat, and ranked 90th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialGlobus Medical has a consensus price target of $99.46, representing about 31.5% upside from its current price of $75.63.Amount of Analyst CoverageGlobus Medical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Globus Medical's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.02% Earnings GrowthEarnings for Globus Medical are expected to grow by 8.02% in the coming year, from $4.99 to $5.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 19.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 19.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.97.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Globus Medical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.18% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Globus Medical has recently increased by 2.22%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.12 News SentimentGlobus Medical has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Globus Medical this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows6 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,413,400.00 in company stock.Percentage Held by Insiders18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Globus Medical's insider trading history. Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMED Stock News HeadlinesRBC Cuts Price Target on Globus Medical to $85 From $115, Keeps Outperform RatingOctober 1 at 7:16 AM | marketscreener.comMReviewing Globus Medical (NYSE:GMED) and CONMED (NYSE:CNMD)October 1 at 5:28 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 3 at 1:00 AM | Profits Run (Ad)Globus Medical (GMED) Pulls Back Following Recent Weakness, Is The Stock Trading At A Discount?September 29, 2026 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesSeptember 29, 2026 | americanbankingnews.comGlobus Medical (GMED)September 25, 2026 | fr.investing.comTranscript : Globus Medical, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 12:45 PMSeptember 24, 2026 | marketscreener.comMQ2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty StocksSeptember 24, 2026 | finance.yahoo.comSee More Headlines GMED Stock Analysis - Frequently Asked Questions How have GMED shares performed this year? Globus Medical's stock was trading at $87.39 at the beginning of 2026. Since then, GMED stock has decreased by 13.5% and is now trading at $75.6250. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings results on Thursday, August, 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. The company's revenue was up 5.9% on a year-over-year basis. Read the conference call transcript. Is Globus Medical buying back stock? Globus Medical's Board of Directors approved a stock buyback plan on Thursday, May 15th 2025, which authorizes the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 6.3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's leadership believes its stock is undervalued. When did Globus Medical IPO? Globus Medical (GMED) raised $200 million in an initial public offering on Friday, August 3rd 2012. The company issued 11,764,705 shares at a price of $16.00-$18.00 per share. Who are Globus Medical's major shareholders? Top institutional investors of Globus Medical include Versant Capital Management Inc. Insiders that own company stock include David D Davidar, Stephen T Zarrilli, Ann D Rhoads, James R Tobin, Leslie V Norwalk, Kyle Kline, Kelly Huller, Keith W Pfeil, Daniel T Scavilla and Dan Lemaitre. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Globus Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today10/03/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, GMED's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:GMED CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees6,000Year Founded2003Price Target and Rating Average Price Target for Globus Medical$99.46 High Price Target$123.00 Low Price Target$80.00 Potential Upside/Downside+31.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$3.91 Trailing P/E Ratio19.34 Forward P/E Ratio15.16 P/E Growth1.2Net Income$537.87 million Net Margins17.02% Pretax Margin20.99% Return on Equity14.57% Return on Assets12.62% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio2.93 Sales & Book Value Annual Sales$2.94 billion Price / Sales3.45 Cash Flow$6.39 per share Price / Cash Flow11.84 Book Value$33.86 per share Price / Book2.23Miscellaneous Outstanding Shares134,260,000Free Float109,585,000Market Cap$10.15 billion OptionableOptionable Beta0.96 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:GMED) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globus Medical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
